Sign In
Buy TBPH
$16.86
+0.0100 (+0.0593%)
At Close: Jul 31, 2026
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP
09:00am, Thursday, 26'th Mar 2026
Theravance Biopharma Reaffirmed Financial Guidance Repeatedly Without Disclosing the Material Risk That Its Pivotal Trial Could Fail Theravance Biopharma Reaffirmed Financial Guidance Repeatedly Witho
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
09:00am, Wednesday, 25'th Mar 2026
Theravance Biopharma Told Investors R&D Costs Were Declining Following Completion of CYPRESS Enrollment NEW YORK, March 25, 2026 /PRNewswire/ -- Theravance Biopharma (NASDAQ: TBPH) shareholders lost a
Theravance's Q4 Earnings and Revenues Miss Estimates
03:46pm, Friday, 20'th Mar 2026
TBPH's posts Q4 earnings miss despite 145% revenue surge; scraps Ampreloxetine, launches restructuring and weighs a potential sale.
All You Need to Know About Theravance Bio (TBPH) Rating Upgrade to Strong Buy
01:01pm, Friday, 20'th Mar 2026
Theravance Bio (TBPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here's Why Theravance Biopharma (TBPH) is a Strong Growth Stock
10:45am, Friday, 20'th Mar 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag Estimates
10:41am, Thursday, 19'th Mar 2026
Theravance Biopharma (TBPH) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.44 per share. This compares to a loss of $0.05 per share a year ago.
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
08:30am, Thursday, 19'th Mar 2026
Organizational restructuring and cost reduction plan following results of the Phase 3 CYPRESS study of ampreloxetine are underway; expected to generate $60 - $70 million of annualized cash flow starti
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP
10:00am, Wednesday, 18'th Mar 2026
Theravance Biopharma Reaffirmed Financial Guidance Repeatedly Without Disclosing the Material Risk That Its Pivotal Trial Could Fail NEW YORK, March 18, 2026 /PRNewswire/ -- Theravance Biopharma (NASD
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
09:00am, Wednesday, 11'th Mar 2026
Theravance Biopharma Told Investors R&D Costs Were Declining Following Completion of CYPRESS Enrollment NEW YORK, March 11, 2026 /PRNewswire/ -- Theravance Biopharma (NASDAQ: TBPH) shareholders lost a
TBPH ALERT: Levi & Korsinsky Investigates Theravance Biopharma, Inc. for Possible Securities Fraud Violations
12:09pm, Tuesday, 10'th Mar 2026
New York, New York--(Newsfile Corp. - March 10, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Theravance Biopharma, Inc. ("Theravance Biopharma, Inc.") (NASDA
Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)
10:35am, Monday, 09'th Mar 2026
Theravance Bio (TBPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings esti
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $22.60 Consensus PT from Brokerages
01:30am, Monday, 09'th Mar 2026
Theravance Biopharma, Inc. (NASDAQ: TBPH - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the company, MarketBe
Down 30.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)
10:35am, Friday, 06'th Mar 2026
The heavy selling pressure might have exhausted for Theravance Bio (TBPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street anal
TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study
11:35am, Wednesday, 04'th Mar 2026
Theravance Biopharma shares plummet 26% after its phase III CYPRESS study of ampreloxetine missed key endpoints, prompting the company to halt the program.
Theravance Biopharma Plummets As Phase 3 Study Falls Short
01:19pm, Tuesday, 03'rd Mar 2026
Theravance Biopharma Inc. (NASDAQ: TBPH) shares are tumbling on Tuesday following the company's Phase 3 CYPRESS study did not meet its primary endpoint.
